These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 21036355)
1. Impact of atorvastatin and omega-3 ethyl esters 90 on plasma plant sterol concentrations and cholesterol synthesis in type 2 diabetes: a randomised placebo controlled factorial trial. Neil HA; Ceglarek U; Thiery J; Paul S; Farmer A; Holman RR Atherosclerosis; 2010 Dec; 213(2):512-7. PubMed ID: 21036355 [TBL] [Abstract][Full Text] [Related]
2. Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial. Holman RR; Paul S; Farmer A; Tucker L; Stratton IM; Neil HA; Diabetologia; 2009 Jan; 52(1):50-9. PubMed ID: 19002433 [TBL] [Abstract][Full Text] [Related]
3. Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia. Maki KC; Bays HE; Dicklin MR; Johnson SL; Shabbout M J Clin Lipidol; 2011; 5(6):483-92. PubMed ID: 22108152 [TBL] [Abstract][Full Text] [Related]
4. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Atorvastin Lipid Intervention (DALI) Study Group Diabetes Care; 2001 Aug; 24(8):1335-41. PubMed ID: 11473066 [TBL] [Abstract][Full Text] [Related]
5. Effects of atorvastatin and omega-3 fatty acids on LDL subfractions and postprandial hyperlipemia in patients with combined hyperlipemia. Nordøy A; Hansen JB; Brox J; Svensson B Nutr Metab Cardiovasc Dis; 2001 Feb; 11(1):7-16. PubMed ID: 11383326 [TBL] [Abstract][Full Text] [Related]
6. The effect of atorvastatin on serum lipoproteins in acromegaly. Mishra M; Durrington P; Mackness M; Siddals KW; Kaushal K; Davies R; Gibson M; Ray DW Clin Endocrinol (Oxf); 2005 Jun; 62(6):650-5. PubMed ID: 15943824 [TBL] [Abstract][Full Text] [Related]
7. Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes. Thomason MJ; Colhoun HM; Livingstone SJ; Mackness MI; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Fuller JH; Diabet Med; 2004 Aug; 21(8):901-5. PubMed ID: 15270795 [TBL] [Abstract][Full Text] [Related]
8. Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes. Betteridge DJ; Gibson JM Diabet Med; 2007 May; 24(5):541-9. PubMed ID: 17367312 [TBL] [Abstract][Full Text] [Related]
10. Comparative lipid-lowering effects of policosanol and atorvastatin: a randomized, parallel, double-blind, placebo-controlled trial. Cubeddu LX; Cubeddu RJ; Heimowitz T; Restrepo B; Lamas GA; Weinberg GB Am Heart J; 2006 Nov; 152(5):982.e1-5. PubMed ID: 17070175 [TBL] [Abstract][Full Text] [Related]
11. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome. Robinson JG; Ballantyne CM; Hsueh WA; Rosen JB; Lin J; Shah AK; Tomassini JE; Lowe RS; Tershakovec AM J Clin Lipidol; 2013; 7(4):292-303. PubMed ID: 23890516 [TBL] [Abstract][Full Text] [Related]
12. Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised-controlled trial. Diepeveen SH; Verhoeven GW; Van Der Palen J; Dikkeschei LD; Van Tits LJ; Kolsters G; Offerman JJ; Bilo HJ; Stalenhoef AF J Intern Med; 2005 May; 257(5):438-45. PubMed ID: 15836660 [TBL] [Abstract][Full Text] [Related]
13. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial. Stender S; Schuster H; Barter P; Watkins C; Kallend D; Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130 [TBL] [Abstract][Full Text] [Related]